Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook

Eli Lilly & Company (NYSE:LLY) posted revenues of astir $19.3 cardinal successful the 4th fourth of 2025, exceeding Street projections of $18 billion, acknowledgment mostly to beardown results from its diabetes and obesity drugs Mounjaro and Zepbound.

The institution announced fiscal twelvemonth 2026 gross forecast of $80-$83 cardinal and non-GAAP EPS forecasts of $33.50-$35.00 per share, beating the expert mean projections of $78 cardinal successful gross and $33.09 per share.

Eli Lilly & Company (NYSE:LLY) further confirmed the instauration of Orforg successful the US successful Q2 2026 arsenic good arsenic the implementation of Medicare’s obesity sum connected July 1, 2027, successful summation to the submission of Orforg’s European record for Type 2 diabetes.

Eli Lilly & Company (NYSE:LLY) is simply a large planetary pharmaceutical institution that develops, manufactures, and distributes a wide scope of drugs. Founded successful 1876, it has grown to go 1 of the world’s largest pharmaceutical companies.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.